去纤苷的中国上市信息以及购买途径、药物价格？

As of October 31, 2023, defibrotide has not yet been launched in China, so patients can choose to purchase defibrinoside that is available overseas.

About

Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties. The most common include abnormally low blood pressure (hypotension), diarrhea, vomiting, nausea, and nosebleeds (epistaxis). Identified serious potential side effects include bleeding (bleeding) and allergic reactions. People with bleeding complications or who are taking blood thinners or other medications that reduce the body's ability to form clots should not use defibrotide.

Defibrotide is the first FDA-approved treatment for severe veno-occlusive disease (VOD), a rare and life-threatening liver disease.

Countries where defibrotide is listed

Defibrotide was approved for medical use in the EU in October 2013, in Japan in March 2019, in Canada in September 2017, in France and Germany in October 2013, in South Korea in February 2016, in the United States in March 2016, and in Australia in July 2020.

Defibrinoside China listing information

As of October 31, 2023, defibrotide has not yet been launched in China, so patients cannot purchase this drug in hospital pharmacies and pharmacies in China. The launch time of defibrotide in China is unclear.

Defibrinoside and where to buy it

The Irish biopharmaceutical company Jazz Pharmaceuticals (JAZZ) version of defibrotide has a reference price of about $21,505 per box.

The purchase methods of defibrinoside are as follows:

1. Hospital pharmacy:

You can go abroad to buy medicines by yourself, and buy fiber glycosides in pharmacies of foreign hospitals. When you go to the hospital, bring your doctor's prescription with you so the pharmacist can provide the correct medicine.

2. Outpatient pharmacies:

Some outpatient departments will have pharmacies for patients to purchase commonly used drugs, including defibrinoside. When purchasing medications at outpatient pharmacies, it is recommended to bring a doctor's prescription.

3. Online pharmacies:

Some regular online pharmacies also provide fibres. Before purchasing medications, make sure you choose a reliable, reputable online pharmacy and make sure it has legal licenses and qualifications.

4. Choose overseas medical service institutions:

Such as medical companion travel, this method is cost-effective, convenient and fast. A third-party drug purchase contract is signed with the patient, and the quality of the drugs is guaranteed. For specific drug purchase procedures, please consult the medical companion travel service.

No matter which purchasing method is used, it is recommended to pay attention to the following points when purchasing drugs:

1. Make sure the medicines you buy are genuine and avoid buying fake and shoddy medicines.

2. Pay attention to the validity period of medicines and choose unexpired medicines.

3. Keep the invoice or receipt for purchasing medicines for future use when you need to inquire or return medicines.

The therapeutic effect of defibrotide

Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is an unpredictable disease associated with endothelial cell damage caused by pretreatment for hematopoietic stem cell transplantation (HSCT) or chemotherapy without HSCT. Mortality rates in patients with VOD/SOS and multiple organ dysfunction (MOD) may be >80%.

Defibrotide is the only drug approved for the treatment of severe hepatic VOD/SOS after HSCT in the EU and hepatic VOD/SOS associated with renal or pulmonary dysfunction in the United States. Its efficacy in VOD/SOS patients with MOD after HSCT was demonstrated in a clinical trial program that included a historical controlled treatment study, a Phase 2 trial, and a large T-IND expanded access program that also included patients without MOD and patients receiving chemotherapy without HSCT.

Defibrinoside appears to protect endothelial cells and restore the thrombolytic-fibrinolytic balance. It addresses an important clinical need and demonstrated favorable +100-day survival and overall adverse event rates similar to those in the control group who received only supportive care, with one analysis showing reduced incidence of VOD/SOS following intravenous defibrination.

Summary

Defibrotide is not currently on the market in China, so patients in need can purchase it overseas or through other methods. However, they should pay attention to purchasing drugs from regular channels to avoid buying fake and inferior drugs that may endanger their health.

Recommended related articles: